Analysis of drug resistance of second-line anti-TBdrugs to baseline strain in patients with multidrug-resistant pulmonary tuberculosis / 中国现代医生
China Modern Doctor
; (36): 84-87, 2018.
Article
en Zh
| WPRIM
| ID: wpr-1037950
Biblioteca responsable:
WPRO
ABSTRACT
Objective To investigate the resistance of second-line anti-TBdrugs to baseline strain in patients with multidrug-resistant pulmonary tuberculosis. Methods Atotal of 52 baseline strains in patients with multidrug-resistant pulmonary tuberculosis collected from March 2016 to May 2017 in our hospital were randomly selected. The sensitivity of the nine kinds of second-line anti-TBdrugs was tested, to analyze the proportion of different drug resistance and cross-resistance of similar drugs. Results Among the 9 second-line anti-TBdrugs, the ratio of drug resistance was ofloxacin =levofloxacin(59. 6%, 31/52)>moxifloxacin(30. 8%, 16/52)> amikacin=kanamycin(both 9. 6%,5/52)>paminosalicylic acid=cycloserine(both 7. 7%, 4/52)> capreomycin =prothionamide(both 9. 6%, 3/52). Ofloxacin was completely cross-resistant with levofloxacin, and its cross-resistant rate with moxifloxacin accounted for 51. 6% (15/31). Amikacin was completely cross-resistant with kanamycin, and its cross-resistant rate with capreomycin accounted for 60%. Conclusion The baseline strains of patients with multi-drug resistant pulmonary tuberculosis are seriously resistant to fluoroquinolones. There is resistance to some extent for other second-line anti-tuberculosis drugs. Therefore, second-line drug susceptibility testing should be completed prior to establishing an effective MDR-TBtreatment regimen.
Texto completo:
1
Banco de datos:
WPRIM
Idioma:
Zh
Revista:
China Modern Doctor
Año:
2018
Tipo del documento:
Article